Table of Content

1. Introduction to Europe Biosimilar Market


2. Development of Biosimilars in Europe
2.1 Development of First Biosimilar Omnitrope: Genotropin
2.2 Second Wave of Biosimilars Development in Europe


3. Significance of Biosimilars in Europe Pharmaceutical Market


4. Off Patents: Biosimilar Opportunity Ahead


5. Europe Biosimilars Approval & Commercialization by Country


6. EMA Approved & Marketed Cancer Biosimilars: Dosage & Price Analysis
6.1 Biosimilars of Bevacizumab
6.2 Biosimilar to MabThera
6.3 Biosimilar of Trastuzumab


7. EMA Approved & Marketed Biosimilars in Blood Disorders: Dosage & Price Analysis
7.1 Biosimilar of Filgrastim
7.2 Biosimilar of Pegfilgrastim
7.3 Biosimilar of Enoxaparin Sodium


8. EMA Approved & Marketed Biosimilars in Diabetes: Dosage & Price Analysis
8.1 Biosimilar of Insuling Glargine
8.2 Biosimilar of Insulin Aspartate
8.3 Biosimilar of Insulin Lispro


9. EMA Approved & Marketed Biosimilars in Chronic Autoimmune Diseases: Dosage & Price Analysis
9.1 Biosimilar of Adalimumab
9.2 Biosimilar of Etanercept
9.3 Biosimilar of Infliximab


10. EMA Approved & Marketed Biosimilars in Other Therapeutic Indications: Dosage & Price Analysis
10.1 Biosimilar of Teriparatide
10.2 Biosimilar of Somatropin
10.3 Biosimilar of Follitropin Alfa
10.4 Biosimilar of Epoetin Alfa


11. Europe Biosimilar Market Insight
11.1 Market Overview
11.2 Current Market Scenario


12. Europe Biosimilar Market by Indication
12.1 Cancer
12.2 Autoimmune Diseases
12.3 Diabetes
12.4 Blood Disorders


13. Europe Biosimilar Clinical Trials By Company, Indication & Phase
13.1 Unknown
13.2 Research
13.3 Clinical
13.4 Phase-I
13.5 Phase-III
13.6 Preregistration
13.7 Registered


14. Europe Marketed Biosimilar Clinical Insight By Company, Drug Class & Indication


15. European Biosimilar Market Trends by Country
15.1 Austria
15.2 Belgium
15.3 Hungary
15.4 Italy
15.5 Norway
15.6 Poland
15.7 Spain
15.8 Sweden
15.9 Switzerland
15.10 UK
15.11 Germany
15.12 France
15.13 Denmark


16. Europe Vs. Global Biosimilar Market Scenarios
16.1 Europe vs. US Biosimilar Market
16.2 Europe vs. India Biosimilar Market
16.3 Europe vs. China Biosimilar Market
16.4 Europe vs. Japan Biosimilar Market
16.5 Europe vs. South Korea Biosimilar Market


17. Europe Biosimilar Market Dynamics
17.1 Favorable Market Parameters
17.2 Europe Biosimilar Market Challenges


18. Europe Biosimilar Market Future Prospects


19. Competitive Landscape
19.1 Accord Healthcare
19.2 Amgen
19.3 AstraZeneca
19.4 Boehringer Ingelheim
19.5 Eli Lilly & Company
19.6 Merck
19.7 Mylan Pharmaceuticals
19.8 Novartis
19.9 Pfizer
19.10 Sanofi
19.11 Takeda Pharmaceuticals
19.12 Teva Pharmaceutical